Inhibition of complement C1s by sutimlimab (SUT) in patients with cold agglutinin disease (CAD): results on efficacy and safety from the randomized, placebo-controlled phase 3 CADENZA study (NCT03347422)

被引：0
|
作者：
Roeth, A. [1 ]
Berentsen, S. [2 ]
Barcellini, W. [3 ]
D'Sa, S. [4 ]
Jilma, B. [5 ]
Michel, M. [6 ]
Weitz, I. C. [7 ]
Yamaguchi, M. [8 ]
Nishimura, J. -i [9 ]
Vos, J. M. [10 ,11 ]
Storek, M. [12 ]
Wong, N. W. [12 ]
Patel, P. [12 ]
Jiang, X. [12 ]
Vagge, D. [13 ]
Wardecki, M. [14 ]
Shafer, F. [12 ]
Lee, M. [12 ]
Broome, C. M. [15 ]
机构：
[1] Univ Hosp Essen, Dept Hematol & Stem Cell Transplantat, West German Canc Ctr, Essen, Germany
[2] Haugesund Hosp, Dept Res & Innovat, Haugesund, Norway
[3] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[4] Univ Coll London Hosp NHS Fdn Trust, UCLH Ctr Waldenstroms Macroglobulinemia & Related, London, England
[5] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria
[6] UPEC, Henri Mondor Univ Hosp, Assistance Publ Hop Paris, Creteil, France
[7] USC, Keck Sch Med, Jane Anne Nohl Div Hematol, Dept Med, Los Angeles, CA USA
[8] Ishikawa Prefectural Cent Hosp, Dept Hematol, Kanazawa, Japan
[9] Osaka Univ, Osaka, Japan
[10] Amsterdam UMC, Amsterdam, Netherlands
[11] Sanquin, Dept Hematol, Amsterdam, Netherlands
[12] Sanofi, Cambridge, England
[13] IQVIA, Bangalore, Karnataka, India
[14] Sanofi, Warsaw, Poland
[15] MedStar Georgetown Univ Hosp, Div Hematol, Washington, DC USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V575
引用
收藏
页码：172 / 173
页数：2
相关论文
共 50 条
  • [21] Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program
    Gelbenegger, Georg
    Schoergenhofer, Christian
    Derhaschnig, Ulla
    Buchtele, Nina
    Sillaber, Christian
    Fillitz, Michael
    Schenk, Thomas M.
    D'Sa, Shirley
    Cartwright, Ronwyn
    Gilbert, James C.
    Jilma, Bernd
    Jaeger, Ulrich
    BLOOD ADVANCES, 2020, 4 (06) : 997 - 1005
  • [22] Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)
    Jilma, Bernd
    Roman, Eloy
    Ueda, Yasutaka
    Mappa, Silvia
    Szamosi, Johan
    Savage, Jessica
    Roeth, Alexander
    BLOOD, 2022, 140 : 5326 - 5327
  • [23] Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo-Controlled, Phase 3 Study
    Deodhar, Atul
    Supronik, Jerzy
    Kivitz, Alan
    Valenzuela, Guillermo
    Kapur, Karen
    Rohrer, Susanne
    Dokoupilova, Eva
    Richards, Hanno B.
    Pavelka, Karel
    ARTHRITIS & RHEUMATOLOGY, 2024,
  • [24] Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
    Kinoshita, Yoshikazu
    Sakurai, Yuuichi
    Takabayashi, Nobuyoshi
    Kudou, Kentaro
    Araki, Takahiro
    Miyagi, Takuya
    Iwakiri, Katsuhiko
    Ashida, Kiyoshi
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2019, 10
  • [25] Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study
    Anders, Hans-Joachim
    Chan, Tak Mao
    Sanchez-Guerrero, Jorge
    Wofsy, David
    Bensley, Karen
    Kim, Lilianne
    Lo, Kim Hung
    Shu, Cathye
    Shao, Jie
    Karyekar, Chetan S.
    Diamond, Betty
    RHEUMATOLOGY, 2024,
  • [26] Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)
    Jilma, Bernd
    Gilbert, James C.
    Panicker, Sandip
    Parry, Graham C.
    Fillitz, Michael
    Thomas, Schenk
    Sillaber, Christian
    Bartko, Johann
    Jaeger, Ulrich
    BLOOD, 2016, 128 (22)
  • [27] Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: Results from a phase 2, randomized, placebo-controlled study
    Terui, Tadashi
    Okubo, Yukari
    Kobayashi, Satomi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB50 - AB50
  • [28] Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
    Terui, Tadashi
    Okubo, Yukari
    Kobayashi, Satomi
    Sano, Shigetoshi
    Morita, Akimichi
    Imafuku, Shinichi
    Tada, Yayoi
    Abe, Masatoshi
    Yaguchi, Masafumi
    Uehara, Natsuka
    Handa, Takahiro
    Tanaka, Masayuki
    Zhang, Wendy
    Paris, Maria
    Murakami, Masamoto
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (05) : 837 - 847
  • [29] Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study
    Tadashi Terui
    Yukari Okubo
    Satomi Kobayashi
    Shigetoshi Sano
    Akimichi Morita
    Shinichi Imafuku
    Yayoi Tada
    Masatoshi Abe
    Masafumi Yaguchi
    Natsuka Uehara
    Takahiro Handa
    Masayuki Tanaka
    Wendy Zhang
    Maria Paris
    Masamoto Murakami
    American Journal of Clinical Dermatology, 2023, 24 : 837 - 847
  • [30] Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase 3 Study
    Kivitz, Alan
    Sedova, Liliana
    Churchill, Melvin
    Kotha, Roshan
    Singhal, Atul
    Torres, Alexander
    Valenzuela, Guillermo
    Whelan, Sarah
    Dumortier, Thomas
    Zhu, Xuan
    Martin, Ruvie
    Pricop, Luminita
    ARTHRITIS & RHEUMATOLOGY, 2024,
12345